Literature DB >> 29726955

Involvement of partial EMT in cancer progression.

Masao Saitoh1.   

Abstract

The epithelial-mesenchymal transition (EMT) provides an outstanding example of cellular plasticity during embryonic development and cancer progression. During EMT in embryonic development, epithelial cells lose all vestiges of their epithelial origin and acquire a fully mesenchymal phenotype, known as complete EMT, which is typically characterized by a so-called cadherin switch. Conversely, during EMT in cancer progression, cancer cells that originate from epithelial cells exhibit both mesenchymal and epithelial characteristics, that is the hybrid E/M phenotype in a process known as partial EMT. Partial EMT in cancer cells is thought to enhance their invasive properties, generate circulating tumour cells and cancer stem cells, and promote resistance to anti-cancer drugs. These phenotypic changes are regulated by extracellular matrix components, exosomes and soluble factors, which regulate several transcription factors known as EMT transcription factors. In this review, I summarize our current understanding of the EMT program during cancer progression.

Entities:  

Mesh:

Year:  2018        PMID: 29726955     DOI: 10.1093/jb/mvy047

Source DB:  PubMed          Journal:  J Biochem        ISSN: 0021-924X            Impact factor:   3.387


  137 in total

1.  Upregulation of miRNA-1228-3p alleviates TGF-β-induced fibrosis in renal tubular epithelial cells.

Authors:  Huajuan Shen; Qiang He; Yongze Dong; Lina Shao; Yueming Liu; Jianguang Gong
Journal:  Histol Histopathol       Date:  2020-07-28       Impact factor: 2.303

2.  TGF-β promote epithelial-mesenchymal transition via NF-κB/NOX4/ROS signal pathway in lung cancer cells.

Authors:  Mingze Ma; Fengxian Shi; Ruonan Zhai; Hang Wang; Ke Li; Chunyan Xu; Wu Yao; Fang Zhou
Journal:  Mol Biol Rep       Date:  2021-04-01       Impact factor: 2.316

3.  Systematic evaluation of the anti-tumor effect of Phellinus linteus polysaccharide in thyroid carcinoma in vitro.

Authors:  Kun Yu; Zhuo Tan; Ying Xin
Journal:  Mol Biol Rep       Date:  2022-01-26       Impact factor: 2.316

4.  [Interference of long noncoding RNA FOXCUT inhibits epithelial-mesenchymal transformation and induces mitochondrial injury in nasopharyngeal carcinoma cells].

Authors:  L Gao; X Zhang; S Dou; X Yue; J Yang
Journal:  Nan Fang Yi Ke Da Xue Xue Bao       Date:  2021-08-31

Review 5.  Defining the Hallmarks of Metastasis.

Authors:  Danny R Welch; Douglas R Hurst
Journal:  Cancer Res       Date:  2019-05-03       Impact factor: 12.701

6.  Extracellular vesicles from MDA-MB-231 breast cancer cells stimulated with insulin-like growth factor 1 mediate an epithelial-mesenchymal transition process in MCF10A mammary epithelial cells.

Authors:  Elizabeth Leal-Orta; Javier Ramirez-Ricardo; Alejandra Garcia-Hernandez; Pedro Cortes-Reynosa; Eduardo Perez Salazar
Journal:  J Cell Commun Signal       Date:  2021-07-26       Impact factor: 5.782

Review 7.  EMT, MET, Plasticity, and Tumor Metastasis.

Authors:  Basil Bakir; Anna M Chiarella; Jason R Pitarresi; Anil K Rustgi
Journal:  Trends Cell Biol       Date:  2020-08-13       Impact factor: 20.808

8.  A Combined Self-Assembled Drug Delivery for Effective Anti-Breast Cancer Therapy.

Authors:  Hairong Wang; Yawen Zhang; Xiangle Zeng; Wenjun Pei; Ranran Fan; Yushuai Wang; Xiu Wang; Jianchun Li
Journal:  Int J Nanomedicine       Date:  2021-03-23

9.  The transcription factor Rreb1 regulates epithelial architecture, invasiveness, and vasculogenesis in early mouse embryos.

Authors:  Sophie M Morgani; Jie Su; Jennifer Nichols; Joan Massagué; Anna-Katerina Hadjantonakis
Journal:  Elife       Date:  2021-04-30       Impact factor: 8.140

10.  LINC00671 suppresses cell proliferation and metastasis in pancreatic cancer by inhibiting AKT and ERK signaling pathway.

Authors:  Shibin Qu; Kunwei Niu; Jianlin Wang; Jimin Dai; Anutosh Ganguly; Chao Gao; Yuzi Tian; Zhibin Lin; Xisheng Yang; Xuan Zhang; Zhengcai Liu; Haimin Li
Journal:  Cancer Gene Ther       Date:  2020-08-15       Impact factor: 5.987

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.